Research use only. Read more

Metabolic / GLP-1

Tirzepatide

A dual GIP and GLP-1 receptor agonist investigated for superior weight and glycaemic outcomes versus selective GLP-1 agonists.

Research consideration: 40 mg and 68 mg variants are typically pre-mixed cartridge pens.

Quick facts

Molecular weight

4,814 Da

Half-life

120 h

Frequency

weekly

Admins / wk

1

Routes

SubQ

Typical dose

2.50 mg–15.0 mg

Mechanism & positioning

A dual GIP and GLP-1 receptor agonist investigated for superior weight and glycaemic outcomes versus selective GLP-1 agonists.

Researched for: dual GIP / GLP-1 receptor agonism, insulin sensitivity, adipose reduction.

Reconstitution defaults

Default vial

10 mg

BAC water

2 mL

Concentration

5000 mcg/mL

Doses per vial

~4

Other stocked vial sizes: 30, 40, 68 mg.

Calculate with this peptide

Documented pairwise interactions

  • avoid

    Tirzepatide + Semaglutide

    Both are long-acting incretin-class agents; stacking compounds gastric and metabolic effects.

  • avoid

    Tirzepatide + Retatrutide

    Both are multi-receptor incretin agonists; concurrent use exceeds any published research protocol.

References

  • Frias JP et al., NEJM, 2021.
  • Jastreboff AM et al., NEJM, 2022.

Related peptides in the Metabolic / GLP-1 class

Frequently asked questions about Tirzepatide

What is the typical research dose range for Tirzepatide?
Tirzepatide is most commonly investigated at 2.50 mg–15.0 mg per administration, weekly. Note: weekly titration. These values reflect documented research-stage protocols and are not medical recommendations.
What is the half-life of Tirzepatide?
Tirzepatide has an approximate plasma half-life of 120 hours. Practical steady state is reached after roughly five half-lives — about 25 days under continuous administration.
How is Tirzepatide administered in research protocols?
Published research uses subq administration. Typical reconstitution is 10 mg vial in 2 mL of bacteriostatic water, producing a concentration of 5000 mcg/mL.
What vial sizes are commonly available for Tirzepatide?
Common stocked vial sizes are 10 mg, 30 mg, 40 mg, 68 mg. The 10 mg vial is the most-used default in published protocols.
Anything important to know about Tirzepatide before designing a protocol?
40 mg and 68 mg variants are typically pre-mixed cartridge pens.